Papers published in national and international conferences or symposium proceedings (43)
  1. 39. Anderton, B., Brion, J. P., Flament Durand, J., Haugh, M., Kahn, J., Miller, C., Probst, A., & Ulrich, J. (1986). Changes in the neuronal cytoskeleton in aging and disease. In M. Bergener, M. Ermini, & N. B. Stähelin (Eds.), Dimensions in Aging. (pp. 69-89) London, UK: Academic Press.
  2. 40. Brion, J. P., Passareiro, H., & Flament Durand, J. (1986). Neurofibrillary tangles of Alzheimer's disease.: Ultrastructural and immunohistochemical study. In P. Vezzadi, A. Facchini, & G. Labo (Eds.), Neuroendocrine System and Aging. (pp. 229-244) Rijswijk, The Netherlands: Eurage Publication.
  3. 41. Anderton, B., Brion, J. P., Flament Durand, J., Haugh, M., Kahn, J., Miller, C., Probst, A., & Ulrich, J. (1986). The neuronal cytoskeleton and neurofibrillary tangles. In M. Briley, A. Kato, & M. Weber (Eds.), New Concepts in Alzheimer's Disease. (pp. 35-52) Basingstoke, UK: Macmillan Press.
  4. 42. Brion, J. P., van den Bosch de Aguilar, P., & Flament Durand, J. (1985). Senile dementia of the Alzheimer type: Morphological and Immunocytochemical Studies. In J. Traber & W. Gispen (Eds.), Advances in Applied Neurological Sciences: Senile Dementia of the Alzheimer type. Early diagnosis.: Vol. 2 (pp. 164-174) Berlin, Heidelberg, Germany: Springer Verlag.
  5. 43. Flament Durand, J., Brion, J. P., & Couck, A. M. (1984). New morphological data observed in Human Brains with Senile Dementia of the Alzheimer type (SDAT). In D. L. Knook, G. Calderini, & L. Amaducci (Eds.), Topics in Aging Research in Europe.: Vol. 2 (pp. 65-70) Rijswijk, The Netherlands: EURAGE.
    6.   Active participation in international conferences and symposiums (59)
  6. 1. De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models.. Vol. 130 (p. 176) Abstract session presented at International conference on Alzheimer and Parkinson’s diseases(15-22 mars 2022: Barcelona).
  7. 2. De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2022). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice.. Vol. 145 (p. 411) Abstract session presented at International conference on Alzheimer and Parkinson's diseases(15-20 Mars 2022: Barcelona).
  8. 3. De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. Paper session presented at International conference on Alzheimer and Parkinson's diseases (15-22 March 2022: Barcelona).
  9. 4. De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2021). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. (p. 54) Abstract session presented at Oral presentation to the Third Eurotau meeting(October 25-26,: Lille, France).
  10. 5. Kosa, A.-C., Ando, K., Lasri, H., Yilmaz, Z., Doeraene, E., López Gutiérrez, L., De Decker, R., Mansour, S., Suain, V., & Brion, J. P. (2021). Deletion of murine APP accelerates cognitive deficits in a murine model of amyloid and tau pathologies. (p. 129) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium.).
  11. 6. De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2021). Intravenous injection of PHF-tau proteins from Alzheimer brain exacerbates neuroinflammation, amyloid beta and tau pathologies in APP/PS1 transgenic mice. (p. 98) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).
  12. 7. Doeraene, E., Erneux, C., Yilmaz, Z., Mansour, S., Suain, V., Turbant, S., Duyckaerts, C., Brain Bank NeuroCEB Neuropathology Network,, Schurmans, S., Brion, J. P., Leroy, K., & Ando, K. (2021). Protein level and solubility of the PI 5-phosphatase SHIP2 is altered in correlation with amyloid pathology in Alzheimer’s brains. (p. 102) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).
    13. << Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Next >>